Abiopharma

🔍 Massacesi Cristian (Executive)

Company: BRISTOL MYERS SQUIBB CO (BMY)

Report Date: 2026-03-10

Detailed Transactions and Holdings:

• Acquired 26,122 shares of Market Share Units (Derivative)
  Date: 2026-03-10 | Code: A | Expires: 2029-03-10 | equity_swap_involved: 0 | shares_owned_after: 26,122.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 39,184 shares of Performance Shares (Derivative)
  Date: 2026-03-10 | Code: A | Expires: 2029-03-10 | equity_swap_involved: 0 | shares_owned_after: 39,184.00 | transaction_form_type: 4 | Footnotes: F3, F3

Footnotes:

• F1: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is the greater of Total Return and relative total shareholder return (rTSR) Floor. Total Return is a ratio of the 10-day average closing stock price on the measurement date, plus the value of accumulated dividends, divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor for Total Return performance that must be achieved to earn a payout is 80% and the maximum is 225%. The rTSR Floor feature provides a minimum level of payout if BMS stock price declines from the grant date but outperforms our peers based on their TSR percentile rank. A TSR percentile rank (i) below the 50th percentile yields a 0% payout, (ii) between the 50th and 74.99th percentiles yields a 50% payout, and (iii) at or above the 75th percentile yields a 100% payout.
• F2: These market share units cliff vest on the third anniversary of the grant date, subject to certification of performance results by the Board.
• F3: Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2029, subject to certification of performance results by the Board.
• REMARKS: Exhibit 24 - Power of Attorney